Abliva AB (publ) (ABLI.ST)
SEK 0.44
(0.23%)
SEK 0.44
(0.23%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 16.78 Million SEK | -14.13% |
| 2022 | 19.54 Million SEK | 12.37% |
| 2021 | 17.39 Million SEK | 68.83% |
| 2020 | 10.3 Million SEK | -50.23% |
| 2019 | 20.69 Million SEK | 13.12% |
| 2018 | 18.29 Million SEK | 28.31% |
| 2017 | 14.25 Million SEK | 14.87% |
| 2016 | 12.41 Million SEK | -38.39% |
| 2015 | 20.14 Million SEK | -14.0% |
| 2014 | 23.42 Million SEK | 61.19% |
| 2013 | 14.53 Million SEK | 71.74% |
| 2012 | 8.46 Million SEK | 410.74% |
| 2011 | 1.65 Million SEK | 69.52% |
| 2010 | 977.43 Thousand SEK | -12.86% |
| 2009 | 1.12 Million SEK | 75.07% |
| 2008 | 640.74 Thousand SEK | -47.48% |
| 2007 | 1.22 Million SEK | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 10.29 Million SEK | -38.63% |
| 2024 Q2 | 8.27 Million SEK | -19.65% |
| 2023 FY | 16.78 Million SEK | -14.13% |
| 2023 Q1 | 7.64 Million SEK | -60.89% |
| 2023 Q2 | 13.63 Million SEK | 78.4% |
| 2023 Q4 | 16.78 Million SEK | 26.61% |
| 2023 Q3 | 13.25 Million SEK | -2.79% |
| 2022 Q1 | 41.57 Million SEK | 139.06% |
| 2022 FY | 19.54 Million SEK | 12.37% |
| 2022 Q4 | 19.54 Million SEK | -10.54% |
| 2022 Q3 | 21.84 Million SEK | 15.95% |
| 2022 Q2 | 18.84 Million SEK | -54.68% |
| 2021 Q3 | 21.94 Million SEK | 18.4% |
| 2021 Q4 | 17.39 Million SEK | -20.76% |
| 2021 FY | 17.39 Million SEK | 68.83% |
| 2021 Q1 | 18.14 Million SEK | 76.12% |
| 2021 Q2 | 18.53 Million SEK | 2.18% |
| 2020 Q4 | 10.3 Million SEK | 13.86% |
| 2020 Q3 | 9.04 Million SEK | -41.07% |
| 2020 Q1 | 8.63 Million SEK | -58.28% |
| 2020 FY | 10.3 Million SEK | -50.23% |
| 2020 Q2 | 15.35 Million SEK | 77.8% |
| 2019 FY | 20.69 Million SEK | 13.12% |
| 2019 Q2 | 19.55 Million SEK | 45.45% |
| 2019 Q1 | 13.44 Million SEK | -26.5% |
| 2019 Q3 | 15.27 Million SEK | -21.92% |
| 2019 Q4 | 20.69 Million SEK | 35.52% |
| 2018 Q3 | 13.18 Million SEK | -1.3% |
| 2018 Q4 | 18.29 Million SEK | 38.8% |
| 2018 Q1 | 15.44 Million SEK | 8.32% |
| 2018 FY | 18.29 Million SEK | 28.31% |
| 2018 Q2 | 13.35 Million SEK | -13.53% |
| 2017 Q4 | 14.25 Million SEK | 80.15% |
| 2017 Q2 | 10.17 Million SEK | 27.89% |
| 2017 FY | 14.25 Million SEK | 14.87% |
| 2017 Q1 | 7.95 Million SEK | -35.94% |
| 2017 Q3 | 7.91 Million SEK | -22.17% |
| 2016 Q2 | 10.28 Million SEK | -48.37% |
| 2016 FY | 12.41 Million SEK | -38.39% |
| 2016 Q1 | 19.9 Million SEK | -1.19% |
| 2016 Q4 | 12.41 Million SEK | 17.18% |
| 2016 Q3 | 10.59 Million SEK | 3.04% |
| 2015 Q4 | 20.14 Million SEK | -30.87% |
| 2015 FY | 20.14 Million SEK | -14.0% |
| 2015 Q3 | 29.14 Million SEK | 36.88% |
| 2015 Q2 | 21.29 Million SEK | -11.01% |
| 2015 Q1 | 23.92 Million SEK | 2.13% |
| 2014 Q1 | 14.47 Million SEK | -0.39% |
| 2014 Q2 | 9.01 Million SEK | -37.73% |
| 2014 FY | 23.42 Million SEK | 61.19% |
| 2014 Q4 | 23.42 Million SEK | 141.64% |
| 2014 Q3 | 9.69 Million SEK | 7.54% |
| 2013 Q4 | 14.53 Million SEK | 64.71% |
| 2013 Q2 | 7.51 Million SEK | -5.77% |
| 2013 Q1 | 7.97 Million SEK | -5.83% |
| 2013 Q3 | 8.82 Million SEK | 17.5% |
| 2013 FY | 14.53 Million SEK | 71.74% |
| 2012 Q1 | 3.29 Million SEK | 98.61% |
| 2012 Q2 | 6.36 Million SEK | 93.44% |
| 2012 Q3 | 4.72 Million SEK | -25.78% |
| 2012 Q4 | 8.46 Million SEK | 79.11% |
| 2012 FY | 8.46 Million SEK | 410.74% |
| 2011 Q4 | 1.65 Million SEK | 43.98% |
| 2011 FY | 1.65 Million SEK | 69.52% |
| 2011 Q1 | 742.1 Thousand SEK | -24.08% |
| 2011 Q3 | 1.15 Million SEK | -57.32% |
| 2011 Q2 | 2.69 Million SEK | 263.32% |
| 2010 Q4 | 977.43 Thousand SEK | 35.8% |
| 2010 Q3 | 719.76 Thousand SEK | -62.45% |
| 2010 FY | 977.43 Thousand SEK | -12.86% |
| 2010 Q2 | 1.91 Million SEK | -70.26% |
| 2010 Q1 | 6.44 Million SEK | 474.68% |
| 2009 FY | 1.12 Million SEK | 75.07% |
| 2009 Q4 | 1.12 Million SEK | 0.0% |
| 2008 FY | 640.74 Thousand SEK | -47.48% |
| 2007 FY | 1.22 Million SEK | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Alzinova AB (publ) | 9.33 Million SEK | -79.841% |
| Amniotics AB (publ) | 10.54 Million SEK | -59.107% |
| Asarina Pharma AB (publ) | 4.42 Million SEK | -279.146% |
| BioArctic AB (publ) | 139.5 Million SEK | 87.971% |
| Calliditas Therapeutics AB (publ) | 1.56 Billion SEK | 98.928% |
| Genovis AB (publ.) | 98.04 Million SEK | 82.885% |
| LIDDS AB (publ) | 3.75 Million SEK | -346.778% |
| Magle Chemoswed Holding AB (publ) | 123.97 Million SEK | 86.465% |
| OncoZenge AB (publ) | 1.69 Million SEK | -887.699% |
| Saniona AB (publ) | 86.08 Million SEK | 80.506% |
| Simris Alg AB (publ) | 148.93 Million SEK | 88.733% |
| Vicore Pharma Holding AB (publ) | 40.85 Million SEK | 58.929% |
| AcouSort AB (publ) | 10.37 Million SEK | -61.698% |
| Active Biotech AB (publ) | 13.4 Million SEK | -25.231% |
| Camurus AB (publ) | 414.81 Million SEK | 95.955% |
| Cantargia AB (publ) | 54.97 Million SEK | 69.472% |
| Scandinavian ChemoTech AB (publ) | 3.83 Million SEK | -337.233% |
| Guard Therapeutics International AB (publ) | 18.49 Million SEK | 9.262% |
| Mendus AB (publ) | 51.22 Million SEK | 67.241% |
| Kancera AB (publ) | 17.97 Million SEK | 6.658% |
| Karolinska Development AB (publ) | 11.56 Million SEK | -45.051% |
| Lipum AB (publ) | 7.53 Million SEK | -122.619% |
| Lipigon Pharmaceuticals AB (publ) | 5.15 Million SEK | -225.339% |
| NextCell Pharma AB | 13.68 Million SEK | -22.587% |
| Xbrane Biopharma AB (publ) | 482.17 Million SEK | 96.52% |
| Xintela AB (publ) | 14.01 Million SEK | -19.736% |
| Ziccum AB (publ) | 6.38 Million SEK | -162.696% |
| Elicera Therapeutics AB (publ) | 13.77 Million SEK | -21.852% |
| Modus Therapeutics Holding AB (publ) | 2.35 Million SEK | -611.361% |
| Isofol Medical AB (publ) | 19.16 Million SEK | 12.435% |
| Xspray Pharma AB (publ) | 71.85 Million SEK | 76.644% |
| CombiGene AB (publ) | 4.15 Million SEK | -303.778% |
| Diamyd Medical AB (publ) | 71.11 Million SEK | 76.404% |
| Intervacc AB (publ) | 21.68 Million SEK | 22.597% |
| Alligator Bioscience AB (publ) | 106.59 Million SEK | 84.257% |
| Sprint Bioscience AB (publ) | 34.6 Million SEK | 51.504% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 26.7 Million SEK | 37.169% |
| Corline Biomedical AB | 6.78 Million SEK | -147.179% |
| IRLAB Therapeutics AB (publ) | 61.35 Million SEK | 72.65% |
| Bio-Works Technologies AB (publ) | 16.11 Million SEK | -4.12% |
| Aptahem AB (publ) | 8.99 Million SEK | -86.501% |
| Infant Bacterial Therapeutics AB (publ) | 46.18 Million SEK | 63.662% |
| Fluicell AB (publ) | 8.91 Million SEK | -88.233% |
| Biovica International AB (publ) | 34.76 Million SEK | 51.733% |
| Spago Nanomedical AB (publ) | 11.66 Million SEK | -43.821% |
| Egetis Therapeutics AB (publ) | 214.6 Million SEK | 92.18% |
| 2cureX AB (publ) | 2.93 Million SEK | -471.755% |
| I-Tech AB | 16.2 Million SEK | -3.554% |
| Hansa Biopharma AB (publ) | 1.18 Billion SEK | 98.585% |
| Cyxone AB (publ) | 4.69 Million SEK | -257.499% |
| ExpreS2ion Biotech Holding AB (publ) | 13.32 Million SEK | -25.908% |
| Biosergen AB | 5.08 Million SEK | -230.01% |
| Nanologica AB (publ) | 79.32 Million SEK | 78.846% |
| SynAct Pharma AB | 51.83 Million SEK | 67.625% |
| Annexin Pharmaceuticals AB (publ) | 7.94 Million SEK | -111.108% |
| BioInvent International AB (publ) | 90.45 Million SEK | 81.448% |
| Stayble Therapeutics AB (publ) | 5.19 Million SEK | -223.026% |
| Oncopeptides AB (publ) | 181.59 Million SEK | 90.759% |
| Pila Pharma AB (publ) | 1.79 Million SEK | -835.396% |
| Ascelia Pharma AB (publ) | 12.74 Million SEK | -31.678% |
| Diagonal Bio AB (publ) | 7.26 Million SEK | -131.143% |